





# Towards high sensitivity and low dose medical imaging with laser X-ray sources

D. Stutman, N. Safca, E. Anghel, I. Ciobanu, and C.A. Ur

Extreme Light Infrastructure - Nuclear Physics / IFIN-HH

**Presents C.A. Ur** 









### Medical applications of high-power lasers



### **Project included in the Romanian Health Program**

- in collaboration with UMFCD Bucharest, IOCN Cluj Napoca, IRO Iasi, POLITEHNICA Bucharest and 2 SMEs
- 35 MEUR for 5 years contract signed on 20.02.2025 co-funded by EU and Romanian Government

#### **Laser-driven C-ions for hadron therapy**

- 10 PW-class lasers have potential to accelerate heavy-ions to therapeutic energy and dose, at ultrahigh dose rate, in few mm
- laser-driven ultra-high dose rate heavy-ion irradiation can enable the FLASH effect (healthy tissue sparring) (10<sup>10</sup> Gy/s)
- Proposed medical focus on long term: start from skin-level cancer, progressing to HNC and breast cancer (#1 cause of cancer mortality for women)

## Interferometric phase contrast X-ray imaging

- Conventional, absorption-contrast X-ray imaging has poor visibility of soft tissue tumors
- Phase-contrast X-ray imaging investigated as alternative
- Method requires intense, directional, short-pulse and spatially coherent X-ray source: 100 TW class lasers can do this
- Proposed medical focus: breast cancer and later lung cancer

## Medical interest radioisotopes production


- High power lasers offer an advantageous alternative for producing medical radioisotopes due to their ability to accelerate different types of particles
- "on-site" production of short-lived, medically relevant radioisotopes, such as <sup>11</sup>C, <sup>13</sup>N or <sup>15</sup>O, becomes more affordable with lasers
- 100 TW-class high repetition rate laser sufficient for radioisotope production







### Poor soft tissue visibility and high dose in conventional absorption-contrast X-ray imaging



- Due to weak X-ray photoelectric absorption at clinical energies (20-120 keV)
- Conventional solutions: i) decrease energy (mammography) => dose increase
  - ii) many views (computed tomography) => dose increase









### Phase-contrast imaging can strongly increase soft tissue visibility and decrease dose

### X-ray phase shift vs. absorption in breast tissue fibril



### Refraction angle in fibril (30 keV X-rays)




- Refraction-based imaging -> object can be transparent -> dose can be strongly decreased
- Challenge: in soft tissues X-ray refraction angles < 1 μrad</li>








### Grating interferometry most sensitive X-ray phase contrast imaging method



breast tissue fibril in adipose tissue 30 keV



< 1 µrad refraction angles

> 2-3 μm feasible grating periods


Multi-meter long interferometers for sufficient angular sensitivity

### 6 m long, 2.4 μm period X-ray interferometer demonstrated at ELI-NP

### Operated with 2 kW X-ray tube at 40 kV

# X-ray-tube Reast phantom 5.7 m

## Simultaneous ultrahigh angular sensitivity and high fringe visibility



N Safca et al SPIE 2022

- Interferometer works with very broad X-ray spectra  $\Delta E/\langle E \rangle \leq 100 \%$  (Stutman et al SPIE 2023)
- Simulations indicate lengths up to 10 m feasible
- Result made possible by extreme stability of ELI-NP 1500 ton "optical table" antivibration platform








# Strongly increased visibility of objects simulating breast cancer and potential for order of magnitude dose reduction

Fibrils in mammography accreditation phantom



Minutes exposure per image with conventional X-ray tube

-> new kind of X-ray source needed for clinical implementation of this concept








Directional and intense X-ray sources produced by 200 TW-class lasers could be ideal for clinical interferometric mammography

**ICS** 0.2 mGy

Simulation of interferometric mammography with 200 TW betatron and ICS-like sources (6 m length, 2.4 μm period interferometer, 10-shot phase scans, <E>=33 keV)


**Refraction images of 400** um breast tissue fibril in adipose tissue


Dark field images of 540 μm and 160 μm diameter calcifications




**Betatron** 2 mGy










0.02 mGy




**Experiment with 40 kVp** microfocus tube 3 m, 2.4 μm interferometer 0.15 mGy




- Usable soft tissue contrast at up to 1/100 of the patient dose in conventional mammography
- **Experiment with microfocus X-ray tube supports prediction**

### New ICS scheme proposed for interferometric mammography


### Self-synchronized "all-optical" ICS scheme




### **Electron spectrum with down-ramp N<sub>e</sub>**



## 3x10<sup>9</sup> photons/shot in 20-60 keV band, 20 mrad cone, 2.5 μm diameter/5 μm length source



Photon density on screen at 12.5 m



200 TW betatron sources demonstrated close to interferometric mammography needs (Fourmaux et al 2024)

## Dr. LASER project at ELI-NP (2025-2030) aims to advance interferometric mammography towards clinical implementation


Laser X-ray source

Source grating G0

Beam-splitter grating G1

X-ray detector

### **New 200 TW Experimental Area for medical applications of high-power lasers**




Project's goal







# Tube-based, 3 m length 2.4 $\mu$ m period interferometer to be installed in a hospital for studies of phase contrast imaging on fresh surgical specimens





- Sensitive interferometry with laser X-ray sources could improve diagnostic and lower dose for patients
- Other laser mechanisms might also make bright µfocus X-ray sources (e.g. "peeler scheme"
   Shen et al 2025, DLA in NCD plasma)
- For medical application in hospitals the lasers must become less costly and more efficient
- Positions for research on medical laser applications at ELI-NP







### Thank you!



"Medical applications of high-power lasers - Dr. Laser"

www.eli-np.ro/projects/drlaser/

SMIS Code: 326475

Project co-financed by the European Union and the Romanian Government within the Romanian Health Program

"This material does not represent the viewpoint of the European Union or the Romanian Government, neither of them being liable for the way the information contained in this presentation might be used."





